RAP-219 Shows Sustained Efficacy in Focal Onset Seizure Trial, Advancing to Phase 3

summarizeSummary

Rapport Therapeutics reported strong follow-up results from its Phase 2a trial of RAP-219 for focal onset seizures, showing sustained and enhanced seizure reduction post-treatment and an extended half-life, paving the way for Phase 3 trials.

check_boxKey Events

• Positive Phase 2a Follow-up Results

  RAP-219 demonstrated sustained and clinically meaningful reductions in long episodes (LEs) and clinical seizures during the 8-week follow-up period after treatment concluded.

• Enhanced Seizure Reduction Post-Treatment

  In weeks 9-12 (first four weeks of follow-up), RAP-219 showed even greater reductions in LEs (80% median) and clinical seizures (90% median) compared to the initial 8-week treatment period.

• Extended Drug Half-Life Confirmed

  The estimated half-life of RAP-219 has been revised to approximately 22 days (up from 14 days), explaining the sustained therapeutic levels and prolonged efficacy.

• Advancement to Phase 3 Trials

  The company plans to initiate two pivotal Phase 3 trials (FOCUS 1 and FOCUS 2) for RAP-219 in focal onset seizures in the second quarter of 2026.

auto_awesomeAnalysis

Rapport Therapeutics announced highly positive follow-up results from its Phase 2a trial of RAP-219 in focal onset seizures (FOS). The data demonstrate sustained and even improved seizure reduction during the 8-week follow-up period after treatment ended, which is a significant positive signal for the drug's long-term efficacy. The estimated half-life of RAP-219 has also been extended to approximately 22 days, which supports the sustained therapeutic levels observed. These results strongly de-risk the program and provide a robust foundation for the planned initiation of two pivotal Phase 3 trials in Q2 2026. This update, following a concurrent news release, provides comprehensive details that are critical for investors assessing the company's clinical pipeline and future growth prospects.